In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency could maintain its pace in reviewing new drug applications.
By the end of the year, the approval picture told a more complicated story, with momentum building after a slow start.
This week on "The Top Line," we dig into what the numbers really show, which companies and therapies came out on top, and what the FDA’s performance over the course of 2025 signals for the drug review process going forward.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
